Vident Advisory’s Ascendis Pharma A/S ASND Stock Holding History

Vident Advisory’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Sell	2,208 -290	-12%	-$67.7K	﹤0.01%	1279
2026 Q1	$571K	Buy	2,498 +572	+30%	+$128K	﹤0.01%	1181
2025 Q4	$411K	Sell	1,926 -98	-5%	-$20.2K	﹤0.01%	1257
2025 Q3	$402K	Buy	2,024 +736	+57%	+$137K	﹤0.01%	1282
2025 Q2	$222K	Sell	1,288 -462	-26%	-$75.3K	﹤0.01%	1454
2025 Q1	$273K	Buy	+1,750	New	+$250K	﹤0.01%	1313

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vident Advisory's ASND Position: Q2 2026 in Review

Vident Advisory reduced its Ascendis Pharma A/S (ASND) stake by 12% in Q2 2026, selling an estimated $67.7K and leaving 2,208 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

Vident Advisory first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Vident Advisory held 2,208 shares of Ascendis Pharma A/S worth $589K as of Q2 2026.
Vident Advisory sold 290 Ascendis Pharma A/S shares in Q2 2026, an estimated $67.7K.
Ascendis Pharma A/S made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1279 holding.
Vident Advisory first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.